Dr. Barry Dworkin

Scientists from Johns Hopkins University have genetically engineered an experimental nanobody that targets alpha-synuclein protein clumps thought to be involved in the pathophysiology of Parkinson’s disease

Medical Mythbusting Commentary for August 9, 2022

[display_podcast]

Source:
Parkinson’s research: Experimental nanobody targets toxic proteins

Reference:
α-Synuclein fibril-specific nanobody reduces prion-like α-synuclein spreading in mice

Related posts:

  1. Vaccine implant destroys cancer tumours in mice
  2. The development of mRNA vaccine technology has the potential to expand to treat and prevent other diseases akin to the technological spinoffs seen with the Apollo space program.
  3. Excellent clinical science produces possible long-term remission for rapidly progessing MS
  4. Interesting approach using monoclonal antibodies to treat Covid-19 infections. However clinical trials must follow to confirm in vitro findings.